Retinopathy of Prematurity (ROP) Diagnosis Time Significantly Reduced Using Telemedicine
Traditional bedside ophthalmoscopy diagnosis can require greater time commitments, according to a study in the American Journal of Ophthalmology
Philadelphia, PA, 29 June 2009 – To be properly diagnosed, retinopathy of prematurity (ROP), the leading cause of childhood blindness in the United States and worldwide, requires a time intensive process and significant coordination between ophthalmologist and NICU staff. A recent study examining ROP diagnosis speed using indirect ophthalmoscopy versus telemedicine, remote medical consultation, is featured in the July issue of the American Journal of Ophthalmology, published by Elsevier.
The study was designed to compare the ophthalmologist’s speed of ROP diagnosis using telemedicine versus traditional bedside ophthalmoscopy. The findings reveal that: 1) ROP diagnosis by the ophthalmologist is significantly faster via telemedicine, and 2) there are significant time requirements by ophthalmologists associated with ROP diagnosis at the NICU bedside beyond ophthalmoscopy. In particular, additional time is taken for travel and communication with families and hospital staff.
To counteract these time requirements the implementation of telemedicine for ROP management has the ability to decrease the time commitment for examining ophthalmologists. Previous studies have shown that telemedical ROP diagnosis is highly accurate and reliable compared with ophthalmoscopy, and future work is required to address workflow questions in more detail.
According to senior author Michael F. Chiang, MD, “Telemedicine has potential to improve the delivery and accessibility of care for infants with ROP by reducing geographical and logistical barriers. This study shows that it may also improve the efficiency of care for ophthalmologists.”
Given the increased number of at-risk infants in the United States and worldwide, improved use of ophthalmology resources may help to prevent cases of avoidable childhood blindness.
# # #
Notes to Editors:
The article is “The Speed of Telemedicine vs Ophthalmoscopy for Retinopathy of Prematurity Diagnosis” by Grace M. Richter, Grace Sun, Thoms C. Lee, R.V. Chuan, John L. Flynn, Justin Starren, and Michael Chiang. It appears in the American Journal of Ophthalmology, Volume 148, Issue 1 (July 2009) published by Elsevier. The full-text article is available to members of the press by contacting the Elsevier press office at firstname.lastname@example.org
About the American Journal of Ophthalmology
The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of theAmerican Journal of Ophthalmology and supplementary material are also presented on the Internet at www.AJO.com
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+1 215 239 3671